General Updates

8th November, 2026 The Corporate Relationship National Stock Exchange of India Department Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”) - Intimation of incorporation of subsidiary in the form of Joint Venture. Dear Sir/Madam, This is in furtherance to our earlier intimations dated 12th August, 2025 and 13th February, 2026 with regard to Shareholders’ Agreement for incorporation of a subsidiary of the Company in the form of a Joint Venture in the Kingdom of Saudi Arabia (JV). Pursuant to Regulation 30 of the SEBI LODR Regulations, we wish to inform you that subsidiary of the Company in the form of a Joint Venture in the name of ‘Alkem Pharma Company’, Limited Liability Company has been incorporated in the Kingdom of Saudi Arabia on 8th November, 2026. Particulars of the disclosure required under SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, have been provided in Annexure – I. Kindly take the same on your records. Sincerely, For Alkem Laboratories Limited Manish Narang President – Legal, Company Secretary & Compliance Officer Annexure – I Sr. Particulars Details a. Name of target entity, details in brief such Name of Joint Venture: ‘Alkem Pharma as size, turnover etc. Company’, Limited Liability Company (“Alkem Pharma”) Capital: 7,500,000.0 SAR divided into 75,000.0 shares of 100 SAR each Turnover: Not Applicable b. Whether the acquisition would fall within The acquisition does not fall under related related party transaction(s) and whether party transaction. the promoter/ promoter group/ group companies have any interest in the entity None of the promoter / promoter group / being acquired? If yes, nature of interest group companies have any interest in the and details thereof and whether the same entity. is done at “arm’s length” c. Industry to which the entity being Pharmaceuticals and Nutraceuticals acquired belongs d. Objects and impact of acquisition The investment in the Subsidiary is a (including but not limited to, disclosure of strategic investment undertaken by the reasons for acquisition of target entity, if Company with the objective of expanding the its business is outside the main line of Company’s business and market reach to the business of the listed entity) Kingdom of Saudi Arabia. e. Brief details of any governmental or Not Applicable regulatory approvals required for the acquisition f. Indicative time period for completion of Not Applicable the acquisition g. Consideration – whether cash Cash consideration consideration or share swap or any other form and details of the same h. Cost of acquisition and/or the price at Subscription of 38,250 Shares of 100 SAR which the shares are acquired e ach amounting to 3,825,000.00 SAR. i. Percentage of shareholding / control 51% of the total share capital of the acquired and / or number of shares Subsidiary. acquired j. Brief background about the entity Brief Background: The Subsidiary is acquired in terms of products/line of incorporated as a limited liability company business acquired, date of incorporation, and will be involved in the manufacture, history of last 3 years turnover, country in import, marketing and distribution of which the acquired entity has presence pharmaceutical and/or nutraceutical products and any other significant information (in within the Kingdom of Saudi Arabia. brief)